No Data
No Data
Akeso's Innovative Cancer Drug Advancing Globally
Akeso (09926.HK): AK112-303/HARMONi-2 have been selected as LBA for the 2024 WCLC and will be orally reported at the plenary session and the chairman's special symposium.
Akeso (09926.HK) announced that the Phase III clinical study (AK112-303/HARMONi2) results of its globally first-in-class bispecific antibody, Idivalimab (PD-1/VEGF) as monotherapy for locally advanced or metastatic non-small cell lung cancer ("NSCLC") patients with PD-L1 TPS ≥ 51% have been selected as Late-Breaking Abstract (LBA) to be presented at the Presidential Symposium of the 2024 World Conference on Lung Cancer (WCLC) organized by the International Association for the Study of Lung Cancer (IASLC). Full data will be presented in an oral report by the principal investigator (PI) Prof. Zhou Caicun during the symposium.
Express News | Akeso - Ak112-303/Harmoni-2 Was Accepted as Lba of 2024 Wclc Presidential Symposium Oral Presentation
Express News | Two Ivonescimab (Pd-1/Vegf) Results Including Phase 3 Monotherapy Versus Pembrolizumab Monotherapy in First-Line Treatment for Pd-L1 Positive Nsclc to Be Presented at Wclc 2024
Akeso, Inc. (HKG:9926) Surges 4.3%; Retail Investors Who Own 37% Shares Profited Along With Institutions
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
No Data
MayFlower : It was predictable..
Midnite52 : yep